Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Opioid-dependent patients often use the emergency department (ED) for medical care. OBJECTIVE: To test the efficacy of 3 interventions for opioid dependence: (1) screening and referral to treatment (referral); (2) screening, brief intervention, and facilitated referral to community-based treatment services (brief intervention); and (3) screening, brief intervention, ED-initiated treatment with buprenorphine/naloxone, and referral to primary care for 10-week follow-up (buprenorphine). DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial involving 329 opioid-dependent patients who were treated at an urban teaching hospital ED from April 7, 2009, through June 25, 2013. INTERVENTIONS: After screening, 104 patients were randomized to the referral group, 111 to the brief intervention group, and 114 to the buprenorphine treatment group. MAIN OUTCOMES AND MEASURES: Enrollment in and receiving addiction treatment 30 days after randomization was the primary outcome. Self-reported days of illicit opioid use, urine testing for illicit opioids, human immunodeficiency virus (HIV) risk, and use of addiction treatment services were the secondary outcomes. RESULTS: Seventy-eight percent of patients in the buprenorphine group (89 of 114 [95% CI, 70%-85%]) vs 37% in the referral group (38 of 102 [95% CI, 28%-47%]) and 45% in the brief intervention group (50 of 111 [95% CI, 36%-54%]) were engaged in addiction treatment on the 30th day after randomization (P < .001). The buprenorphine group reduced the number of days of illicit opioid use per week from 5.4 days (95% CI, 5.1-5.7) to 0.9 days (95% CI, 0.5-1.3) vs a reduction from 5.4 days (95% CI, 5.1-5.7) to 2.3 days (95% CI, 1.7-3.0) in the referral group and from 5.6 days (95% CI, 5.3-5.9) to 2.4 days (95% CI, 1.8-3.0) in the brief intervention group (P < .001 for both time and intervention effects; P = .02 for the interaction effect). The rates of urine samples that tested negative for opioids did not differ statistically across groups, with 53.8% (95% CI, 42%-65%) in the referral group, 42.9% (95% CI, 31%-55%) in the brief intervention group, and 57.6% (95% CI, 47%-68%) in the buprenorphine group (P = .17). There were no statistically significant differences in HIV risk across groups (P = .66). Eleven percent of patients in the buprenorphine group (95% CI, 6%-19%) used inpatient addiction treatment services, whereas 37% in the referral group (95% CI, 27%-48%) and 35% in the brief intervention group (95% CI, 25%-37%) used inpatient addiction treatment services (P < .001). CONCLUSIONS AND RELEVANCE: Among opioid-dependent patients, ED-initiated buprenorphine treatment vs brief intervention and referral significantly increased engagement in addiction treatment, reduced self-reported illicit opioid use, and decreased use of inpatient addiction treatment services but did not significantly decrease the rates of urine samples that tested positive for opioids or of HIV risk. These findings require replication in other centers before widespread adoption. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00913770.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
Generation of allocation sequences in randomised trials: chance, not choice
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07683-3 · Cited by 774
Madras, B. K., Compton, W. M., Avula, D., Stegbauer, T., Stein, J. B., & Clark, H. W. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.08.003 · Cited by 663
CDC grand rounds: prescription drug overdoses - a U.S. epidemic.
(2012) · PubMed · Cited by 494
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
A New Measure of Substance Abuse Treatment Initial Studies of the Treatment Services Review
McLELLAN, A. T., ALTERMAN, A. I., CACCIOLA, J., METZGER, D., & OʼBRIEN, C. P. (1992) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199202000-00007 · Cited by 421
Jonas, D. E., Garbutt, J. C., Amick, H. R., Brown, J. M., Brownley, K. A., Council, C. L., Viera, A. J., Wilkins, T. M., Schwartz, C. J., Richmond, E. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00544 · Cited by 387
Cited by
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
“Opioid prescription 7185 (41) 5039 (41) 598 (42) 917 (41) 265 (34) 366 (43)”
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
The changing opioid crisis: development, challenges and opportunities
Volkow, N. D., & Blanco, C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0661-4 · Cited by 522
A review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J., & El-Haddad, S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.033 · Cited by 445
Management of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Development of a Cascade of Care for responding to the opioid epidemic.
Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1546862 · Cited by 332
Primary Care–Based Models for the Treatment of Opioid Use Disorder: A Scoping Review
Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & Chou, R. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2149 · Cited by 297
Wakeman, S. E., Metlay, J. P., Chang, Y., Herman, G. E., & Rigotti, N. A. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4077-z · Cited by 262
D’Onofrio, G., Chawarski, M. C., O’Connor, P. G., Pantalon, M. V., Busch, S. H., Owens, P. H., Hawk, K., Bernstein, S. L., & Fiellin, D. A. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-3993-2 · Cited by 261
Self-citationOne-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose
Weiner, S. G., Baker, O., Bernson, D., & Schuur, J. D. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.04.020 · Cited by 257
Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1052 · Cited by 255
Englander, H., Dobbertin, K., Lind, B. K., Nicolaidis, C., Graven, P., Dorfman, C., & Korthuis, P. T. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05251-9 · Cited by 234
Touchpoints—opportunities to predict and prevent opioid overdose: a cohort study.
Larochelle, M. R., Bernstein, R., Bernson, D., Land, T., Stopka, T. J., Rose, A. J., Bharel, M., Liebschutz, J. M., & Walley, A. Y. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.06.039 · Cited by 189
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130
Medications for management of opioid use disorder
Koehl, J. L., Zimmerman, D. E., & Bridgeman, P. J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz105 · Cited by 90
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity
Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0685-1 · Cited by 90
Anderson, E. S., Rusoja, E., Luftig, J., Ullal, M., Shardha, R., Schwimmer, H., Friedman, A., Hailozian, C., & Herring, A. A. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.09.025 · Cited by 42
Philippine, T., Forsgren, E., DeWitt, C., Carter, I., McCollough, M., & Taira, B. R. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07862-1 · Cited by 19
Nguemeni Tiako, M. J., Hong, S., Bin Mahmood, S. U., Mori, M., Mangi, A., Yun, J., Juthani-Mehta, M., & Geirsson, A. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000710 · Cited by 13
Sahker, E., Luo, Y., Sakata, M., Toyomoto, R., Hwang, C., Yoshida, K., Watanabe, N., & Furukawa, T. A. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07543-z · Cited by 10
“Other modalities included motivational enhancement,(44,55) brief advice,(51) and brief negotiated interviews.(50) Some used BI combinations in separate arms.”
BackgroundPantalon, M. V., Dziura, J., Li, F.-Y., Owens, P. H., O'Connor, P. G., & D'Onofrio, G. (2017) · Substance Abuse · doi:10.1080/08897077.2017.1294548 · Cited by 7
Self-citationReed, M. K., Siegler, A., Esteves Camacho, T., London, K., Schaeffer, K., & Rising, K. L. (2024) · Substance Use & Misuse · doi:10.1080/10826084.2023.2275561 · Cited by 6
Eide, D., Gjersing, L., Danielsen, A. W., Skulberg, A. K., Dale, O., Braarud, A., Heyerdahl, F., & Tylleskar, I. (2024) · Addiction · doi:10.1111/add.16632 · Cited by 6
Metadata
- Authors
- D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-04-28
- Volume
- 313
- Issue
- 16
- Pages
- 1636
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2158292788
- Cited by
- 910
- References
- 38
- FWCI
- 48.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.